Medlab Clinical reported in line with Morgans' forecasts on a continued operation basis. The major change in the period was the divestment of the Australian nutraceuticals business, providing for opex savings.

The focus now is on drug delivery and development, accelerating news flow around partnering discussions for its two major assets,
and advancing preparatory works for its Ph3 cancer pain trial.

The size, timing, and shape of these deals will be absolutely key, the broker notes, ahead of advancing Medlab's major cancer pain asset given clinical expenditure estimates are currently well in excess of the company's cash balance.

Speculative Buy retained, target rises to 30c from 29c.

Sector: Pharmaceuticals, Biotechnology & Life Sciences.

Target price is $0.30.Current Price is $0.12. Difference: $0.18 - (brackets indicate current price is over target). If MDC meets the Morgans target it will return approximately 60% (excluding dividends, fees and charges - negative figures indicate an expected loss).

© 2022 Acquisdata Pty Ltd., source FN Arena